Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.57 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.57 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.43 |
| ▸ | SCD | O00767 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 8/20 | 0.42 |
| ▸ | GPR183 | P32249 | 1/20 | 0.41 |
| ▸ | CPS1 | P31327 | 2/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4636549 | 0.83 | CPS1 (0.53) | CPS1DPP4 | |
| SCHEMBL4635407 | 0.82 | CYP2C9 (0.52) | SCD | |
| SCHEMBL4635248 | 0.81 | HCRTR1 (0.45) | HCRTR1HCRTR2P2RX7CPS1 | |
| SCHEMBL30810004 | 0.80 | HCRTR1 (0.56) | HCRTR1HCRTR2P2RX7SCDSMO | |
| SCHEMBL4636016 | 0.78 | P2RX7 (0.50) | P2RX7 | |
| SCHEMBL4635078 | 0.76 | KDM1A (0.48) | GPR183SCN9A | |
| SCHEMBL4635545 | 0.76 | EPHX2 (0.45) | P2RX7CPS1SCN9A | |
| SCHEMBL4635417 | 0.76 | TAS1R3 (0.44) | P2RX7SCN9A | |
| SCHEMBL937498 | 0.75 | GPR183 (0.50) | HCRTR1HCRTR2P2RX7SCDSMO | |
| SCHEMBL30691929 | 0.75 | GPR183 (0.50) | HCRTR1HCRTR2P2RX7SCDSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | RANBAXY LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300251-A1 | Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors | DPP4, DPP3, DPP8 | HCRTR1 1802/4885HCRTR2 1658/4885P2RX7 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.